Annual report pursuant to Section 13 and 15(d)

Business and Organization (Details)

v3.8.0.1
Business and Organization (Details)
$ / shares in Units, $ in Millions
1 Months Ended 12 Months Ended
Aug. 31, 2016
USD ($)
$ / shares
shares
Dec. 31, 2017
person
Transition Therapeutics, Inc.    
Business Acquisition [Line Items]    
Total purchase price | $ $ 58.5  
Common Stock    
Business Acquisition [Line Items]    
Stock price (in dollars per share) | $ / shares $ 9.10  
Common Stock | Transition Therapeutics, Inc.    
Business Acquisition [Line Items]    
Common stock received, in shares (in shares) | shares 6,431,899  
Diagnostics    
Business Acquisition [Line Items]    
Sales force, persons (in persons) | person   400